Overview

Pharmacokinetic Study of Intranasal Dexmedetomidine in Pediatric Patients With Congenital Heart Disease

Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The main objectives of the study are to determine peak plasma drug concentration levels and corresponding time of dexmedetomidine following intranasal administration in children age ≥1 mo to ≤ 6 yr with congenital heart disease undergoing an elective diagnostic or interventional cardiac catheterization procedure.
Phase:
Phase 1
Details
Lead Sponsor:
Children's Hospital of Philadelphia
Treatments:
Dexmedetomidine